Virtual Roadshow with Ayala Pharmaceuticals (AYLA) CEO Roni Mamluk
Originally broadcast LIVE May 6, 2021. Ayala Pharmaceuticals CEO Roni Mamluk makes a formal corporate presentation. Afterwards, she is joined by Noble Capital Markets Senior Research Analyst Robert LeBoyer for a Q & A session featuring questions asked by the live audience throughout the event.
Research, News, and Advanced Market Data on AYLA is available at no cost on Channelchek: https://www.channelchek.com/company/AYLA
Information on upcoming live virtual roadshows is available on Channelchek: https://www.channelchek.com/vrs
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trial for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.
-
Category
No comments found